GT Biopharma Inc. (GTBP) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GTBP SEC filings page.
This page shows GT Biopharma Inc. (GTBP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financing inflows rebuilt the balance sheet, but persistent operating cash outflows remain the dominant business mechanic without reported revenue.
Operating cash flow stayed near-$12.9M in both FY2024 and FY2025, even as the latest accounting loss became much larger. The resulting net-loss/operating-cash gap—FY2025 net loss of-$28.4M versus operating cash flow of-$12.9M —suggests substantial non-cash or non-operating items affected earnings, although the tables do not identify their exact composition.
The balance-sheet reset is substantial: equity moved from
The expense mix shifted in FY2025: research and development fell from
Financial Health Signals
GT Biopharma Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
GT Biopharma Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
GT Biopharma Inc. reported a net loss of $28.4M while operations used $12.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
GT Biopharma Inc. reported an operating loss of $12.4M against $127K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
GT Biopharma Inc. reported -$4.5M in net income in Q2 2026. This represents an increase of 85.0% from the same quarter a year earlier. Against the prior quarter it is down 59.5%.
GT Biopharma Inc. earned -$0.12 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 9.1%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
GT Biopharma Inc. held $5.0M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
GT Biopharma Inc.'s ROE was -126.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is down 89.2 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
GT Biopharma Inc. invested $1.1M in research and development in Q2 2026. This represents an increase of 190.6% from the same quarter a year earlier. Against the prior quarter it is up 155.4%.
Not reported for Q2 2026.
Not reported for Q2 2026.
GTBP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q/A | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q/A |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.1M+190.6% | $413K-62.4% | N/A | $634K-51.5% | $363K-79.7% | $1.1M+41.4% | N/A | $1.3M-4.2% |
| SG&A Expenses | $3.5M+200.6% | $2.4M+192.3% | N/A | $2.7M+19.6% | $1.1M-45.8% | $833K-64.0% | N/A | $2.3M+30.7% |
| Operating Income | -$4.5M-198.2% | -$2.8M-47.4% | N/A | -$3.4M+6.2% | -$1.5M+61.3% | -$1.9M+37.5% | N/A | -$3.6M-15.4% |
| Interest Expense | $64K | $63K | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$4.5M+85.0% | -$2.8M-265.1% | N/A | $8.3M+343.3% | -$30.2M-713.2% | -$776K+65.8% | N/A | -$3.4M-41.2% |
| EPS (Basic) | -$0.12+98.9% | -$0.11+66.7% | $2.22+233.7% | $1.04+168.0% | -$10.92-403.2% | -$0.33+79.9% | -$1.66+23.5% | -$1.53+13.6% |
| EPS (Diluted) | -$0.12 | -$0.11 | $2.22 | $1.04 | -$10.92 | -$0.33 | -$1.66+23.5% | -$1.53 |
| Diluted Shares (Avg) | 39M | 30M | N/A | 4M | 3M | 2M | N/A | 2M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.
GTBP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q/A | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q/A |
|---|---|---|---|---|---|---|---|---|
| Total Assets | N/A | N/A | $8.1M+91.5% | $4.3M-36.1% | $7.1M-23.1% | N/A | $4.2M-70.0% | $6.8M-58.1% |
| Current Assets | $5.8M-18.8% | $10.0M+276.1% | $8.1M+91.5% | $4.3M-36.1% | $7.1M-23.1% | $2.7M-73.1% | $4.2M-69.9% | $6.8M-57.9% |
| Cash & Equivalents | $5.0M-5.1% | $8.9M+277.3% | $6.8M+72.4% | $2.5M-60.6% | $5.2M-43.5% | $2.4M+21.3% | $4.0M+266.2% | $6.4M+142.4% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $0-100.0% | $0-100.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | N/A | N/A | $2.3M-60.7% | $1.3M-71.7% | $33.0M+777.9% | N/A | $5.9M-11.0% | $4.7M-24.1% |
| Current Liabilities | $2.2M-92.9% | $2.4M-33.6% | $2.3M-60.7% | $1.3M-71.7% | $31.0M+725.8% | $3.6M-20.9% | $5.9M-11.0% | $4.7M-8.4% |
| Non-Current Liabilities | N/A | N/A | $0 | $0 | $2.0M | N/A | $0 | $0-100.0% |
| Total Equity | $3.6M+113.8% | $7.6M+873.5% | $5.8M+446.5% | $3.0M+43.1% | -$25.9M-569.8% | -$980K-118.4% | -$1.7M-122.3% | $2.1M-79.0% |
| Retained Earnings | -$731.4M-0.7% | -$726.8M-4.4% | -$723.9M-4.1% | -$718.1M-3.9% | -$726.3M-5.6% | -$696.0M-1.7% | -$695.2M-1.9% | -$691.5M-1.8% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
GTBP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q/A | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q/A |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.3M-41.3% | -$2.5M-12.1% | -$4.0M-62.9% | -$3.7M-34.3% | -$3.0M+14.8% | -$2.2M+47.1% | -$2.5M-20.6% | -$2.7M-39.4% |
| Stock-Based Compensation | N/A | $46K+1433.3% | N/A | N/A | N/A | $3K-97.1% | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | $1K-99.8% | -$1K-100.1% |
| Financing Cash Flow | $297K-94.9% | $4.6M+643.5% | $8.3M | $977K | $5.9M | $616K | $0 | $0 |
| Dividends Paid | N/A | N/A | $144K | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Share Buybacks.
GTBP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q/A | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q/A |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -126.6% | -37.4% | N/A | 276.6%+439.3pp | N/A | N/A | N/A | -162.7%-138.5pp |
| Return on Assets | N/A | N/A | N/A | 192.1%+242.5pp | -423.5%-383.4pp | N/A | N/A | -50.5%-35.5pp |
| Current Ratio | 2.61+2.4x | 4.14+3.4x | 3.50+2.8x | 3.27+1.8x | 0.23-2.2x | 0.73-1.4x | 0.72-1.4x | 1.45-1.7x |
| Debt-to-Equity | N/A | N/A | 0.40 | 0.44-1.8x | N/A | N/A | N/A | 2.22+1.6x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| GT Biopharma Inc. GTBP | FY2025 | N/A | -$28.4M | N/A | $21.0M | — |
| PROTAGENIC THERAPEUTICS PTIX | FY2026 | $0 | $1.4M | N/A | $1.4M | — |
| LIPELLA PHARMS INC LIPO | FY2024 | $536K | -$5.0M | N/A | $11.8M | — |
| Salarius Pharmaceuticals, Inc. SLRX | FY2025 | N/A | $12.5M | N/A | $4.9M | — |
| Scinai Immunotherapeutics Ltd. SCNI | FY2025 | $1.3M | -$8.3M | N/A | $1.1M | 45/100 |
| Virax Biolabs Group Limited VRAX | FY2026 | $12K | -$5.0M | N/A | $2.1M | — |
Where GT Biopharma Inc. Ranks
Frequently Asked Questions
Is GT Biopharma Inc. profitable?
No, GT Biopharma Inc. (GTBP) reported a net income of -$28.4M in fiscal year 2025.
What is GT Biopharma Inc.'s return on equity (ROE)?
GT Biopharma Inc. (GTBP) has a return on equity of -490.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is GT Biopharma Inc.'s operating cash flow?
GT Biopharma Inc. (GTBP) recorded an outflow of $12.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are GT Biopharma Inc.'s total assets?
GT Biopharma Inc. (GTBP) had $8.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does GT Biopharma Inc. spend on research and development?
GT Biopharma Inc. (GTBP) invested $3.5M in research and development during fiscal year 2025.
What is GT Biopharma Inc.'s current ratio?
GT Biopharma Inc. (GTBP) had a current ratio of 3.50 as of fiscal year 2025, which is generally considered healthy.
What is GT Biopharma Inc.'s debt-to-equity ratio?
GT Biopharma Inc. (GTBP) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is GT Biopharma Inc.'s return on assets (ROA)?
GT Biopharma Inc. (GTBP) had a return on assets of -349.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is GT Biopharma Inc.'s P/E ratio?
GT Biopharma Inc. (GTBP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $21.0M as of Sep 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is GT Biopharma Inc.'s price-to-sales ratio?
GT Biopharma Inc. (GTBP) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $21.0M as of Sep 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does GT Biopharma Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, GT Biopharma Inc. (GTBP) held $6.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $12.9M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is GT Biopharma Inc.'s Piotroski F-Score?
GT Biopharma Inc. (GTBP) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are GT Biopharma Inc.'s earnings high quality?
GT Biopharma Inc. (GTBP) reported a net loss of $28.4M while operations used $12.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can GT Biopharma Inc. cover its interest payments?
GT Biopharma Inc. (GTBP) reported an operating loss of $12.4M against $127K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.